spacer
home > pmps > winter 2002 > nasal delivery of vaccines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nasal Delivery of Vaccines

The nasal delivery of vaccines has recently emerged as an attractive alternative to injection. Nasal vaccination has the advantage that it elicits both local and systemic immune responses. The mucosal immune response is rapid and nasal vaccines may also induce protection in distant mucosal sites. Correct formulation and adequate distribution to the nasal mucosa are, however, essential for efficacy and safety. The complexity of nasal geometry represents a major challenge for efficient intranasal vaccination, and current delivery devices may prove inadequate in meeting future safety and reliability requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Per Gisle Djupesland, Founder, Head of R&D and Chairman of OptiNose AS
Dr Per Gisle Djupesland is Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing devices based on a novel technology for the nasal delivery of drugs and vaccines. Dr Djupesland is a specialist in Otorhinolaryngology.

He has a PhD in Nasal Physiology and Aerodynamics from the University of Oslo and has also been Research Fellow at the University of Toronto, Canada. Dr Djupesland holds a degree in International Health and Tropical Medicine from the University of Pierre and Marie Curie in Paris, France, and has been Project Manager for a large-scale vaccination trial for the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CRO and Sponsor Quality Award Finalists Announced by ACRP, The Avoca Group

Washington, DC The Association of Clinical Research Professionals (ACRP) and The Avoca Group will jointly recognize leading Sponsors and CROs at the ACRP Awards & Recognition Ceremony on Friday, May 1, during the ACRP 2020 annual conference in Seattle, Washington.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach combined with therapeutic expertise, regulatory know how, and global presence delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement